Main Street Research’s BioMarin Pharmaceuticals BMRN Stock Holding History

Main Street Research’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-44,426	Closed	-$4.65M	–	98
2015 Q4	$4.65M	Sell	44,426 -745	-2%	-$77.8K	0.99%	42
2015 Q3	$5.29M	Sell	45,171 -42,186	-48%	-$5.64M	1.24%	32
2015 Q2	$11.9M	Buy	87,357 +1,663	+2%	+$206K	2.45%	3
2015 Q1	$10.7M	Buy	85,694 +1,785	+2%	+$189K	2.3%	5
2014 Q4	$7.58M	Buy	83,909 +2,670	+3%	+$222K	1.62%	20
2014 Q3	$5.86M	Buy	81,239 +5,515	+7%	+$362K	1.31%	29
2014 Q2	$4.71M	Buy	75,724 +2,925	+4%	+$177K	1.11%	35
2014 Q1	$4.97M	Buy	72,799 +12,424	+21%	+$916K	1.21%	31
2013 Q4	$4.25M	Buy	60,375 +1,527	+3%	+$104K	1.06%	37
2013 Q3	$4.25M	Buy	58,848 +7,913	+16%	+$526K	1.15%	36
2013 Q2	$2.84M	Buy	+50,935	New	+$3.17M	0.86%	42

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Main Street Research's BMRN Position: Q1 2016 in Review

Main Street Research sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2016, closing a stake of 44,426 shares — an estimated $4.65M sold.

Main Street Research first reported a position in BMRN in Q2 2013 and held it in 11 quarters. The position peaked at $11.9M in Q2 2015. 391 funds tracked by Wall St. Rank hold BMRN as of Q1 2016.

Main Street Research reported no remaining BioMarin Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Main Street Research sold 44,426 BioMarin Pharmaceuticals shares in Q1 2016, an estimated $4.65M.
Main Street Research first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 11 quarters.
Main Street Research's BioMarin Pharmaceuticals position peaked at $11.9M in Q2 2015.
391 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2016.

Based on Main Street Research's 13F filing for Q1 2016, filed 13 May 2016.